Advertisement

Journal of Natural Medicines

, Volume 60, Issue 3, pp 217–224 | Cite as

Inhibitory effect of Yunnan traditional medicines on hepatitis C viral polymerase

  • Michiko Jo
  • Norio Nakamura
  • Nobuko Kakiuchi
  • Katsuko Komatsu
  • Ming-hua Qui
  • Kumiko Shimotohno
  • Kunitada Shimotohno
  • Masao Hattori
Original Paper

Abstract

For the purpose of developing novel anti-hepatitis C virus (HCV) agents from natural resources, 93 Yunnan crude drugs were screened for their inhibitory effects on RNA-dependent RNA polymerase (RdRp) of HCV. Although 71 methanol extracts and 50 water extracts inhibited HCV-RdRp by more than 50% at a concentration of 50 μg/ml, the majority of them contained a high percentage of tannins. However, methanol extracts of Plumbago zeylanica (branch), Maytenus fookerii (leaf) and Huashidancha (Y61, branch and leaf), and water extracts of Potentilla griffithii (whole plant) and Salvia yunnanensis (underground part), having IC50 values of less than 10 μg/ml, showed less than 10% tannin content. In addition, from a methanol extract of Tripterygium hypoglaucum (root bark), demethylzeylasteral was isolated as a strongly inhibitory substance against HCV-RdRp.

Keywords

Tripterygium hypoglaucum Demethylzeylasteral Hepatitis C virus RNA-dependent RNA polymerase Yunnan crude drugs 

References

  1. 1.
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359–362CrossRefPubMedGoogle Scholar
  2. 2.
    Pacini L, Bartholomew L, Vitelli A, Migliaccio G (2004) Reporter substrates for assessing the activity of the hepatitis C virus NS3-4A serine protease in living cells. Anal Biochem 331:46–59CrossRefPubMedGoogle Scholar
  3. 3.
    Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares S, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE, Meeks EL, Beach MJ (1992) The natural history of community-acquired hepatitis C in the United States: the sentinel counties chronic non-A, non-B hepatitis study team. N Engl J Med 327:1899–1905CrossRefPubMedGoogle Scholar
  4. 4.
    Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, Nawrocki M, Kruska L, Hensel F, Petry W, Haussinger D (1998) Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 28:1687–1695CrossRefPubMedGoogle Scholar
  5. 5.
    Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y, Choo QL, Houghton M, Kuo G (1990) Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 87:6547–6549CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sarrazin C, Mihm U, Herrmann E, Welsch C, Albrecht M, Sarrazin U, Traver S, Lengauer T, Zeuzem S (2005) Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection. J Infect Dis 192:1710–1719CrossRefPubMedGoogle Scholar
  7. 7.
    Walker MP, Appleby TC, Zhong W, Lau JY, Hong Z (2003) Hepatitis C virus therapies: current treatments, targets, and future perspectives. Antivir Chem Chemother 14:1–21CrossRefPubMedGoogle Scholar
  8. 8.
    De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G (2003) Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 58:1–16CrossRefPubMedGoogle Scholar
  9. 9.
    No author listed (2005) Hepatitis C update: strategies for treatment, compliance, and long-term health. Am J Manag Care 11:S284–S285Google Scholar
  10. 10.
    Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, Rey FA (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A 23:13034–13049CrossRefGoogle Scholar
  11. 11.
    Behrens SE, Tomei L, De Francesco R (1996) Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 15:12–22PubMedPubMedCentralGoogle Scholar
  12. 12.
    De Francesco R, Migliaccio G (2005) Challenges and successes in developing new therapies for hepatitis C. Nature 436:953–960CrossRefPubMedGoogle Scholar
  13. 13.
    Kimura T, Jyo M, Nakamura N, Komatsu K, Hattori M, Shimotohono K, Shimotohono K, Kakiuchi N (2003) Inhibitory effect of Tibetan medicinal plants on viral polymerases. J Trad Med 20:243–250Google Scholar
  14. 14.
    Dictionary of Chinese Materia Medica (1998) Shanghai Science and Technology, China, Shogakukan, TokyoGoogle Scholar
  15. 15.
    Pharmaceutical Company of Yunnan Province (1993) Yunnan Zhongyao Ziyuan Minglu (The Resource of Chinese Materia Medica in Yunnan). Science Press, Beijing, ChinaGoogle Scholar
  16. 16.
    Jo M, Nakamura N, Kurokawa M, Komatsu K, Shiraki K, Hattori M (2005) Anti-herpes simplex virus activities of traditional Chinese medicines, used in Yunnan and Tibetan provinces of China. J Trad Med 22:321–328Google Scholar
  17. 17.
    Yamashita T, Kaneko S, Shirota Y, Qin WP, Nomura T, Kobayashi K, Murakami S (1998) RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. J Biol Chem 273:15479–15486CrossRefPubMedGoogle Scholar
  18. 18.
    Okuda T, Mouri K, Murakami R (1977) Studies on constituents of Geranii Herba VI. Yakugaku Zasshi 97:1273–1278CrossRefPubMedGoogle Scholar
  19. 19.
    Gamlath CB, Gunaherath GMB, Gunatilaka AAL (1987) Studies on terpenoids and steroids. Part 10. Structures of four new natural phenolic D: A-friedo-24-noroleanane triterpenoids. J Chem Soc Perkin Trans I:2849–2854 Google Scholar
  20. 20.
    Morota T, Yang CX, Ogino T, Qin WZ, Katsuhara T, Xu LH, Komatsu Y, Miao KL, Maruno M, Yang BH (1995) D: A-Friedo-24-noroleanane from Tripterygium wilfordii. Phytochemistry 39:1159–1163CrossRefGoogle Scholar
  21. 21.
    Duan H, Kawazoe K, Bando M, Kido M, Takaishi Y (1997) Di- and tri-terpenoids from Tripterygium hypoglaucum. Phytochemistry 46:535–543CrossRefGoogle Scholar
  22. 22.
    Cyong JC, Kim SM, Iijima K, Kobayashi T, Furuya M (2000) Clinical and pharmacological studies on liver diseases treated with Kampo herbal medicine. Am J Chin Med 28:351–360CrossRefPubMedGoogle Scholar
  23. 23.
    Duan H, Takaishi Y (1998) Structures of sesquiterpene polyol alkaloids from Tripterygium hypoglaucum. Phytochemistry 49:2185–2189CrossRefGoogle Scholar
  24. 24.
    Fujita R, Duan H, Takaishi Y (2000) Terpenoids from Tripterygium hypoglaucum. Phytochemistry 53:715–722CrossRefPubMedGoogle Scholar
  25. 25.
    Zhuang WJ, Fong CC, Cao J, Ao L, Leung CH, Cheung HY, Xiao PG, Fong WF, Yang MS (2004) Involvement of NF-κB and c-myc signaling pathways in the apoptosis of HL-60 cells induced by alkaloids of Tripterygium hypoglaucum (Levl.) Hutch. Phytomedicine 11:295–302Google Scholar
  26. 26.
    Bai JP, Shi YL, Fang X, Shi QX (2003) Effects of demethylzeylasteral and celastrol on spermatogenic cell Ca2+ channels and progesterone-induced sperm acrosome reaction. Eur J Pharmacol 464:9–15CrossRefPubMedGoogle Scholar
  27. 27.
    Ushiro S, Ono M, Nakayama J, Fujiwara T, Komatsu Y, Sugimachi K, Kuwano M (1997) New nortriterpenoid isolated from anti-rheumatoid arthritic plant, Tripterygium wilfordii, modulates tumor growth, and neovascularization. Int J Cancer 72:657–663CrossRefPubMedGoogle Scholar
  28. 28.
    Mashino T, Shimotohno K, Ikegami N, Nishikawa D, Okuda K, Takahashi K, Nakamura S, Mochizuki M (2005) Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives. Bioorg Med Chem Lett 15:1107–1109 CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Pharmacognosy and Springer 2006

Authors and Affiliations

  • Michiko Jo
    • 1
  • Norio Nakamura
    • 1
  • Nobuko Kakiuchi
    • 2
  • Katsuko Komatsu
    • 1
  • Ming-hua Qui
    • 3
  • Kumiko Shimotohno
    • 4
  • Kunitada Shimotohno
    • 5
  • Masao Hattori
    • 1
  1. 1.Institute of Natural MedicineUniversity of ToyamaToyamaJapan
  2. 2.Faculty of Pharmaceutical SciencesKanazawa UniversityKanazawaJapan
  3. 3.Kunming Institute of BotanyThe Chinese Academy of SciencesKunmingPeople’s Republic of China
  4. 4.Kyoritsu University of PharmacyTokyoJapan
  5. 5.Department of Viral Oncology, Institute for Virus ResearchKyoto UniversityKyotoJapan

Personalised recommendations